87 related articles for article (PubMed ID: 2726849)
1. QSAR analysis of acetylcholinesterase inhibitors by use of structure similarity methods.
Jerman-Blazic B; Fabic-Petrac I; Pecar S; Stalc A
Prog Clin Biol Res; 1989; 291():213-6. PubMed ID: 2726849
[TBL] [Abstract][Full Text] [Related]
2. Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE).
Araújo JQ; de Brito MA; Hoelz LV; de Alencastro RB; Castro HC; Rodrigues CR; Albuquerque MG
Eur J Med Chem; 2011 Jan; 46(1):39-51. PubMed ID: 21074294
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
Pan L; Tan JH; Hou JQ; Huang SL; Gu LQ; Huang ZS
Bioorg Med Chem Lett; 2008 Jul; 18(13):3790-3. PubMed ID: 18524585
[TBL] [Abstract][Full Text] [Related]
4. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
5. Construction of the pharmacophore model of acetylcholinesterase inhibitor.
Zhu Y; Tong XY; Zhao Y; Chen H; Jiang FC
Yao Xue Xue Bao; 2008 Mar; 43(3):267-76. PubMed ID: 18630262
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
So SS; Karplus M
J Med Chem; 1997 Dec; 40(26):4360-71. PubMed ID: 9435905
[TBL] [Abstract][Full Text] [Related]
7. Structural bioinformatics and QSAR analysis applied to the acetylcholinesterase and bispyridinium aldoximes.
Mager PP; Weber A
Drug Des Discov; 2003; 18(4):127-50. PubMed ID: 15553925
[TBL] [Abstract][Full Text] [Related]
8. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
Akula N; Lecanu L; Greeson J; Papadopoulos V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6277-80. PubMed ID: 17049234
[TBL] [Abstract][Full Text] [Related]
9. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.
Chaudhaery SS; Roy KK; Saxena AK
J Chem Inf Model; 2009 Jun; 49(6):1590-601. PubMed ID: 19441865
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structure-activity relationships for organophosphates binding to acetylcholinesterase.
Ruark CD; Hack CE; Robinson PJ; Anderson PE; Gearhart JM
Arch Toxicol; 2013 Feb; 87(2):281-9. PubMed ID: 22990135
[TBL] [Abstract][Full Text] [Related]
11. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives.
Rampa A; Bisi A; Valenti P; Recanatini M; Cavalli A; Andrisano V; Cavrini V; Fin L; Buriani A; Giusti P
J Med Chem; 1998 Oct; 41(21):3976-86. PubMed ID: 9767635
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors.
Shen LL; Liu GX; Tang Y
Acta Pharmacol Sin; 2007 Dec; 28(12):2053-63. PubMed ID: 18031622
[TBL] [Abstract][Full Text] [Related]
13. The simulated binding of (+/-)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]meth yl] -1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses.
Inoue A; Kawai T; Wakita M; Iimura Y; Sugimoto H; Kawakami Y
J Med Chem; 1996 Oct; 39(22):4460-70. PubMed ID: 8893840
[TBL] [Abstract][Full Text] [Related]
14. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
[TBL] [Abstract][Full Text] [Related]
15. [Sensitivity of cholinesterases from various sources to organophosphate inhibitors with S-alkyl radicals of various lengths].
Kormilitsyn BN; Moralev SN; Khovanskikh AE; Dalimov DN
Zh Evol Biokhim Fiziol; 2003; 39(5):405-9. PubMed ID: 14689726
[No Abstract] [Full Text] [Related]
16. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
17. Binding orientations, QSAR, and molecular design of thiophene derivative inhibitors.
Liao SY; Chen TJ; Miao TF; Qian L; Zheng KC
Chem Biol Drug Des; 2009 Sep; 74(3):289-96. PubMed ID: 19703031
[TBL] [Abstract][Full Text] [Related]
18. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Opera TI; Waller CL; Marshall GR
Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase.
Rodríguez-Franco MI; Fernández-Bachiller MI; Pérez C; Castro A; Martínez A
Bioorg Med Chem; 2005 Dec; 13(24):6795-802. PubMed ID: 16183292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
